{"entity":{"id":"nurix","kind":"company","name":"Nurix Therapeutics","aka":[],"tldr":"Nurix Therapeutics is developing bexobrutideg, a brain-penetrant BTK degrader in pivotal trials for CLL, co-developed with Roche from June 2026.","summary":"Nurix Therapeutics, based in San Francisco and listed as NRIX, is developing bexobrutideg, a brain-penetrant BTK degrader in pivotal trials for chronic lymphocytic leukaemia, co-developed with Roche from June 2026. Bexobrutideg, or NX-5948, degrades both wild-type and inhibitor-resistant BTK and produced durable responses in relapsed or refractory CLL and small lymphocytic lymphoma, presented orally at EHA 2026; the 2026 plan includes the DAYBreak CLL-201 phase 2 and a confirmatory phase 3. OnCo links it to CLL and diffuse large B-cell lymphoma, to protein degradation and glue discovery platforms, to Roche, and to bottlenecks on acquired resistance and undruggable drivers. Whether a degrader can overcome the BTK mutations that defeat inhibitors in patients is the question its trials will answer. Roche has its own page.","asOf":"2026-09-04","links":[{"label":"Roche collaboration","url":"https://www.roche.com/media/releases/med-cor-2026-06-08"}],"tags":[],"related":[],"cancers":["cll","dlbcl"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":[],"drugs":["bexobrutideg"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07520006","nct07221500"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.nurixtx.com","ticker":"NRIX","investors":[],"funding":[]},"route":"/companies/nurix/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"drug":[{"id":"bexobrutideg","kind":"drug","name":"Bexobrutideg","route":"/drugs/bexobrutideg/"}],"company":[{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"trial":[{"id":"nct07221500","kind":"trial","name":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","route":"/trials/nct07221500/"},{"id":"nct07520006","kind":"trial","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","route":"/trials/nct07520006/"},{"id":"nct07516093","kind":"trial","name":"Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL","route":"/trials/nct07516093/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}],"idea":[{"id":"idea-bio2-brain-penetrant-glue-degraders","kind":"idea","name":"Design protein degraders small enough to get into the brain","route":"/ideas/idea-bio2-brain-penetrant-glue-degraders/"},{"id":"idea-bio1-tumour-restricted-e3-atlas","kind":"idea","name":"Find E3 ligases that only tumours have, and build degraders around them","route":"/ideas/idea-bio1-tumour-restricted-e3-atlas/"},{"id":"idea-bio1-glue-degrader-atlas","kind":"idea","name":"Screen glue-like compounds against every cancer cell line and publish it","route":"/ideas/idea-bio1-glue-degrader-atlas/"},{"id":"idea-bio1-antibody-degrader-conjugates","kind":"idea","name":"Use antibodies to deliver protein-destroying drugs into the right cells","route":"/ideas/idea-bio1-antibody-degrader-conjugates/"}]}}